Vilanterol 25 mcg
Sponsors
GlaxoSmithKline
Conditions
Pulmonary Disease, Chronic Obstructive
Phase 3
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
CompletedNCT01716520
Start: 2012-10-31End: 2013-03-31Updated: 2017-01-09
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02014480
Start: 2013-02-01End: 2013-06-11Updated: 2018-02-15